APLMW — Apollomics, Inc.

Summary of APLMW Q4 2023 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2023, Apollomics reported cash, cash equivalents, and market funds totaling $37.8 million, down from $58.9 million in 2022.
• Funding: The company raised $23.7 million in a PIPE financing in March 2023.
• Expenses:
  • Research and Development (R&D) expenses were $34.2 million, slightly down from $35.4 million in 2022.
  • General and Administrative (G&A) expenses increased significantly to $20.6 million from $9.9 million in 2022, attributed to costs related to the business combination, insurance, and stock-based compensation.
• Net Loss: The net loss for 2023 was $172.6 million, or $2.32 per diluted share, an improvement from a net loss of $240.8 million, or $8.44 per diluted share, in 2022.
• Operating Cash Flow: Net cash used in operating activities was approximately $43.2 million, compared to $42.8 million in the prior year.

2. Strategic Updates and Business Highlights

• Product Development: Significant progress was made on lead drug candidates, vebreltinib (APL-101) and APL-106, with promising clinical results reported.
  • Vebreltinib is in a Phase II registrational trial for non-small cell lung cancer (NSCLC) and other solid tumors with MET dysregulation.
  • The SPARTA Trial has treated over 500 patients across 90 sites globally, showing encouraging efficacy and a safety profile similar to existing MET inhibitors.
• Regulatory Progress: Conditional approval for vebreltinib was received in China for treating MET Exon 14 skipping NSCLC. The company retains rights outside Greater China.
• Upcoming Milestones: The company anticipates presenting new preclinical data at the AACR meeting and expects top-line results from APL-106's pivotal study in AML in Q2 2024.

3. Forward Guidance and Outlook

• Apollomics expects its cash position to fund operations through Q1 2025.
• The company plans to continue enrolling patients in the SPARTA Trial, with potential NDA submissions for vebreltinib anticipated in 2025 for certain indications.
• The focus remains on vebreltinib and APL-106, with no immediate plans to diversify the pipeline further.

4. Bad News, Challenges, or Points of Concern

• Cash Burn: The company faces a significant cash burn rate, with operating expenses expected to remain high due to ongoing clinical trials and the need for additional patient enrollment.
• Regulatory Uncertainty: While there is optimism around FDA feedback, the requirement for additional patient data could delay timelines for NDA submissions.
• Increased Expenses: The rise in G&A expenses raises concerns about financial management, especially as the company transitions to a public entity.

5. Notable Q&A Insights

• FDA Feedback: The FDA advised continued patient enrollment to strengthen the data set for vebreltinib, indicating a need for clarity on the 12-month follow-up timeline.
• CFO Role: Newly appointed CFO Matthew Plunkett emphasized a focus on capital formation and strategic collaborations to enhance financial strategy.
• R&D Expense Projections: Analysts inquired about R&D expenses, with indications that while costs may rise due to patient enrollment, the completion of certain trials could lead to reduced expenses moving forward.

Overall, while Apollomics has made significant strides in drug development and regulatory progress, it faces challenges related to cash management and the need for additional clinical data to support its growth and approval strategies.